Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton,
Ph.D., President and Chief Executive Officer, will present at the Bank
of America Merrill Lynch 2013 Healthcare ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and
financial results for the first quarter ended March 31, 2013.
Quarter and ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S.
Patent number 8,419,686 which relates to the device-injection site
contacting interface. The interface design is applicable to ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the first shipment
of commercial-ready VIBEX™ auto-injector devices to Teva at the end of
the first quarter 2013. This initial order ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and
financial results for the fourth quarter and full year ended December
31, 2012.
... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the New Drug
Application (NDA) for OTREXUP™, a potential new product for the
subcutaneous delivery of methotrexate (MTX) using Medi-Jet™ ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton,
Ph.D., President and Chief Executive Officer, will participate in the
RBC Capital Markets’ Healthcare Conference on Wednesday, ... read more
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a
New Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA) for OTREXUP™, a combination product ... read more